Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results

At a glance

Company: Quantum BioPharma Ltd.
Ticker: NASDAQ: QNTM, CSE: QNTM

Key figures

Patient enrollment progress: halfway point
Quantum BioPharma ownership of UWI as of March 31, 2026: 19.84%
Royalty rate on unbuzzd sales before the stated payment threshold: 7%
Royalty payment threshold: $250 million
Royalty rate after the threshold: 3%

Products and programs

Lucid-MS
unbuzzd

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot MS imaging study with Massachusetts General Hospital, with preliminary PET imaging data showing encouraging signals in acute MS lesions. The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, potentially offering a more precise way to measure myelin loss and repair. “These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation,” reads a recent article. “A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.”

To view the full article, visit https://nnw.fm/fsDHa

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of March 31, 2026) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

Quantum BioPharma says enrollment has reached the midpoint in its pilot multiple sclerosis imaging study with Massachusetts General Hospital. Early PET imaging results have shown signals in acute MS lesions, according to the company. The imaging method is intended to help distinguish nerve fibers affected by demyelination that may remain viable from fibers with permanent damage, potentially improving assessment of myelin loss and repair. The release links the research to Lucid-MS, the company’s investigational compound targeting PAD2, an enzyme it says is implicated in myelin degradation. Quantum BioPharma also describes its broader portfolio and its stake and royalty arrangement involving unbuzzd Wellness Inc. The release does not provide the number of enrolled patients or further detail on the preliminary imaging findings.

Key takeaways

Quantum BioPharma reports that its pilot MS imaging study with Massachusetts General Hospital has reached halfway enrollment.
Preliminary PET data showed signals in acute MS lesions, according to the company.
The imaging approach aims to differentiate potentially viable demyelinated fibers from permanent nerve damage.
The company says the imaging research is relevant to its investigational compound Lucid-MS.

SEC filings

Earlier from Quantum BioPharma Ltd.

Back to News Center